Journal
VIROLOGY
Volume 464, Issue -, Pages 166-176Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.virol.2014.07.011
Keywords
Oral vaccines; Recombinant L. Plantarum NC8-pSIP409-HA; H9N2 virus; Hemagglutinin
Categories
Funding
- National High-Tech R&D Program of China (863 Program) [2013AA102806, 2011AA10A215]
- National Natural Science Foundation of China [31272541, 31272552, 81170358, 31372463]
- National Program on Key Basic Research Project of China (973 Program) [2012CB722202]
- Trans-Century Training Program Foundation for the Talents by the State Education Commission [NCET-10-0175]
- Jilin Province Science and Technology Development Program of China [20111816, 20080104]
- Jilin Province Quality and Safety of Agricultural Products Program by World Bank [2011-Y07]
Ask authors/readers for more resources
The H9N2 avian influenza virus (AN) has become increasingly concerning due to its role in severe economic losses in the poultry industry. Transmission of AN to mammals, including pigs and humans, has accelerated efforts to devise preventive strategies. To develop an effective oral vaccine against H9N2 AIV, a recombinant Lactobacillus plantarum NC8 strain expressing the hemagglutinin (HA) gene of H9N2 AIV was constructed in this study. Mice were orally immunized with the recombinant NC8-pSIP409-HA strain, and sIgA, IgG and HI antibodies were produced by the NC8-pSIP409-HA strain, which also induced CD8(+) T cell immune responses. Most importantly, oral administration produced complete protection against challenge with mouse-adapted H9N2 virus. These results indicate that the recombinant NC8-pSIP409-HA was more effective at inducing the mucosal, humoral and cellular immune responses. Therefore, L. plantarum NC8-pSIP409-HA could become a promising oral vaccine candidate against H9N2 AIV. (C) 2014 Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available